Google, Celgene backing Armo BioSciences’ immunotherapy approach
Armo Biosciences secured an impressive Series C round to advance its lead immunotherapy product into phase 2/3 trials.
Armo Biosciences secured an impressive Series C round to advance its lead immunotherapy product into phase 2/3 trials.